Publicações
Investigação
-
ARP Rheumatol. 2024 Jul-Sep;3(3):182-188. doi: 10.63032/POPM9413.
Antifibrotics in rheumatoid arthritis-associated interstitial lung disease - real-world data from a nationwide cohort.
Pmid:
39368099
-
J Rheumatol. 2024 Apr 1;51(4):378-389. doi: 10.3899/jrheum.2023-0764.
Patient-reported outcomes (PROs) and PRO remission rates in 12,262 biologic-naïve patients with psoriatic arthritis treated with tumor necrosis factor inhibitors in routine care.
Pmid:
38224992
-
Semin Arthritis Rheum. 2024 Apr:65:152388. doi: 10.1016/j.semarthrit.2024.152388.
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
Pmid:
38301349
-
ARP Rheumatol. 2024 Jul 1;3(Apr-Jun):81-82. doi: 10.63032/JBRG6950.
Lessons learnt from the recent recommendations for the non-pharmacological management of systemic sclerosis.
Pmid:
38368546
-
Arthritis Care Res (Hoboken). 2024 Feb;76(2):274-287. doi: 10.1002/acr.25220.
Impact of risk factors on COVID-19 outcomes in unvaccinated people with rheumatic diseases: a comparative analysis of pandemic epochs using the COVID-19 Global Rheumatology Alliance Registry.
Pmid:
37643903
-
ARP Rheumatol. 2024 Jan-Mar;3(1):4-10. doi: 10.63032/ZUZZ7662.
10-year experience of early arthritis clinic at a tertiary rheumatology center: achievements and challenges.
Pmid:
38320200
-
ARP Rheumatol. 2024 Jan-Mar;3(1):18-28. doi: 10.63032/UTGY3244.
Neutrophile to lymphocyte and platelet to lymphocyte ratios predict clinical response to bDMARD in naïve spondylarthritis patients.
Pmid:
38368549
-
Rheumatology (Oxford). 2024 Jul 23:keae370. doi: 10.1093/rheumatology/keae370.
Sex differences in patient-reported outcomes and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.
Pmid:
39041780
-
Scand J Rheumatol. 2024 Jul;53(4):237-247. doi: 10.1080/03009742.2024.2336743.
Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response.
Pmid:
38771017
-
Ann Rheum Dis. 2024 Oct 21;83(11):1584-1595. doi: 10.1136/ard-2024-225869.
actors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.
Pmid:
38816065
-
Pulmonology. 2024 Jan-Feb;30(1):87-89. doi: 10.1016/j.pulmoe.2023.05.009.
Lung disease in rheumatoid arthritis: results from a national cohort.
Pmid:
37394340
-
Joint Bone Spine. 2024 Jul;91(4):105729. doi: 10.1016/j.jbspin.2024.105729.
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment.
Pmid:
38582359
-
Rheumatology (Oxford). 2024 Apr 22:keae236. doi: 10.1093/rheumatology/keae236.
Risk of chronic kidney disease in 260 patients with lupus nephritis-analysis of a nationwide multicentre cohort with up to 35 years of follow-up.
Pmid:
38648778
-
Rheumatology (Oxford). 2024 Mar 1;63(3):751-764. doi: 10.1093/rheumatology/kead284.
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.
Pmid:
37314967
-
J Rheumatol. 2023 Aug;50(8):1009-1019. doi: 10.3899/jrheum.220459.
One-third of European patients with axial spondyloarthritis reach pain remission with routine care tumor necrosis factor inhibitor treatment.
Pmid:
36455943
-
Arthritis Rheumatol. 2024 Apr;76(4):587-598. doi: 10.1002/art.42758.
Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network.
Pmid:
37975166
-
ARP Rheumatol. 2023 Apr-Jun;2(2):132-140.
Effectiveness of biosimilar infliximab CT-P13 compared to originator infliximab in biological-naïve patients with rheumatoid arthritis and axial spondyloarthritis: data from the Portuguese Register.
Pmid:
37421191
-
J Multidiscip Healthc. 2023 Apr 26:16:1127-1139. doi: 10.2147/JMDH.S404017. eCollection 2023.
Myositis multidisciplinary clinic in a tertiary referral center.
Pmid:
37131932
-
Joint Bone Spine. 2024 Mar;91(2):105671. doi: 10.1016/j.jbspin.2023.105671.
Evaluation and comparison of oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: results from the international TOCERRA and PANABA observational collaborative studies.
Pmid:
38042363
-
Rheumatology (Oxford). 2024 Jul 1;63(7):1882-1892. doi: 10.1093/rheumatology/kead494.
Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration.
Pmid:
37738257
-
Rheumatology (Oxford). 2024 Jul 1;63(7):1882-1892. doi: 10.1093/rheumatology/kead494.
Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching.
Pmid:
37738257
-
ARP Rheumatol. 2023 Apr-Jun;2(2):111-119.
Severe infections in Portuguese patients with rheumatoid arthritis under biologic treatment - a multicenter, nationwide study (SIPPRA-B Study).
Pmid:
37421190
-
Lancet Reg Health Eur. 2023 Aug 4:33:100706. doi: 10.1016/j.lanepe.2023.100706. eCollection 2023 Oct.
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe.
Pmid:
37601339
-
Arthritis Res Ther. 2023 Sep 21;25(1):177. doi: 10.1186/s13075-023-03166-9.
Influence of the timing of biological treatment initiation on Juvenile Idiopathic Arthritis long-term outcomes.
Pmid:
37735435
-
ARP Rheumatology 2023;2:200-210
Cycling versus swapping strategies in psoriatic arthritis: results from the Rheumatic Diseases Portuguese Register.
Pmid:
37728133
-
ARP Rheumatol. 2023;2:188–199.
The idiopathic inflammatory myopathies module of the Rheumatic Diseases Portuguese Register.
Pmid:
37728117
-
Clin Rheumatol. 2023 May 8. doi: 10.1007/s10067-023-06617-5.
Assessment of calcinosis in Portuguese patients with systemic sclerosis - a multicenter study
Pmid:
37154983
-
Front Immunol. 2023 Mar 8;14:1146817. doi: 10.3389/fimmu.2023.1146817.
Predictors of cardiac involvement in idiopathic inflammatory myopathies
Pmid:
36969246
-
Ann Rheum Dis. 2023 Feb;82(2):175-181. doi: 10.1136/ard-2022-222835.
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries
Pmid:
36100351
-
ARP Rheumatol. 2023 Jan-Mar;2(1):47-52.
FRAX 10-year fracture risk in rheumatoid arthritis assessed with and without bone mineral density - are we treating our patients under bDMARDs?
Pmid:
36739534
-
Ann Rheum Dis. 2022 Oct;81(10):1358-1366. doi: 10.1136/annrheumdis-2022-222586.
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
Pmid:
35705376
-
Ann Rheum Dis. 2022 Oct;81(10):1358-1366. doi: 10.1136/annrheumdis-2022-222586.
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
Pmid:
35705376
-
Rheumatology (Oxford). 2022 Aug 30;61(9):3799-3807. doi: 10.1093/rheumatology/keab945.
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response
Pmid:
34940840
-
ACR Open Rheumatol. 2022 Aug 24. doi: 10.1002/acr2.11495.
Characteristics and outcomes of people with gout hospitalized due to COVID-19: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Pmid:
36000538
-
Semin Arthritis Rheum. 2022 Oct;56:152081. doi: 10.1016/j.semarthrit.2022.152081.
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration
Pmid:
35985172
-
RMD Open. 2022 Jul;8(2):e002322. doi: 10.1136/rmdopen-2022-002322.
SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
Pmid:
35908834
-
ACR Open Rheumatol. 2022 Jul 22. doi: 10.1002/acr2.11481.
Development of a prediction model for COVID-19 acute respiratory distress syndrome in patients with rheumatic diseases: results from the Global Rheumatology Alliance registry
Pmid:
35869686
-
ARP Rheumatol. Apr-Jun 2022;1(2):109-116.
Effectiveness and safety of original and biosimilar etanercept (Enbrel® vs Benepali®) in bDMARD-naïve patients in a real-world cohort of Portugal
Pmid:
35810368
-
Front Med (Lausanne). 2022 Jun 13;9:901817. doi: 10.3389/fmed.2022.901817. eCollection 2022.
Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in ratients with inflammatory rheumatic diseases in Portugal— a multicenter, nationwide study
Pmid:
35770002
-
Adv Rheumatol. 2022 Jun 10;62(1):20. doi: 10.1186/s42358-022-00251-6.
Spotlight on latent tuberculosis infection screening for juvenile idiopathic arthritis in two countries, comparing high and low risk patients.
Pmid:
35689240
-
ARP Rheumatol. 2022 Jan-Mar;1(1):12-20.
Predictive factors of relapse after methotrexate discontinuation in juvenile idiopathic arthritis patients with inactive disease.
Pmid:
35633573
-
ARP Rheumatol. Jan-Mar 2022; 1(1):21-29.
Clinical features and outcome of 1054 patients with Systemic Sclerosis: analysis of Reuma.pt/SSc registry.
Pmid:
35633574
-
ARP Rheumatol. Jan-Mar 2022; 1(1):42-48.
Sex differences in axial spondyloarthritis: data from a Portuguese spondyloarthritis cohort.
Pmid:
35633576
-
Rheumatology (Oxford). 2022 Nov 28;61(12):4741-4751. doi: 10.1093/rheumatology/keac174.
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis.
Pmid:
35323903
-
RMD Open. 2022 Feb;8(1):e001955. doi: 10.1136/rmdopen-2021-001955.
Measuring quality of life of patients with axial spondyloarthritis for economic evaluation.
Pmid:
35177554
-
Ann Rheum Dis. 2022 May;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490.
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.
Pmid:
34972811
-
Rheumatology (Oxford). 2022 Aug 30;61(9):3799-3807. doi: 10.1093/rheumatology/keab945.
European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response.
Pmid:
34940840
-
Lancet Rheumatol. 2021 Dec;3(12):e855-e864. doi: 10.1016/S2665-9913(21)00316-7.
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study.
Pmid:
34778843
-
RMD Open. 2021 Nov; 7(3):e001766. doi: 10.1136/rmdopen-2021-001766.
Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases.
Pmid:
34819385
-
Clin Rheumatol. 2022 Apr;41(4):1139-1144. doi: 10.1007/s10067-021-05997-w.
Gender differences in clinical features and outcomes of a Portuguese systemic sclerosis cohort
Pmid:
34799767
-
RMD Open. 2021 Nov; 7(3):e001818. doi: 10.1136/rmdopen-2021-001818.
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology.
Pmid:
34789534
-
Ann Rheum Dis. 2021 Nov; 80(11):1410-1418. doi: 10.1136/annrheumdis-2021-220097. Epub 2021 Jun 3.
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Pmid:
34083206
-
Rheumatology (Oxford). 2021 Oct 2;60(10): 4717-4727. doi:10.1093/rheumatology/keab083.
Happiness, quality of life and their determinants among people with systemic sclerosis: a structural equation modelling approach.
Pmid:
33521812
-
JAMA Netw Open. 2021 Oct 1; 4(10):e2129639. doi: 10.1001/jamanetworkopen. 2021.29639.
Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19.
Pmid:
34661663
-
Ann Rheum Dis. 2021 Sep;80(9):1137-1146. doi: 10.1136/annrheumdis-2021-220418. Epub 2021 May 28.
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Pmid:
34049860
-
Acta Reumatol Port. Jul-Sep 2021; 46(3):257-265.
Ten years of a systemic sclerosis clinic in a tertiary referral centre - insights and future directions.
Pmid:
34628459
-
Ann Rheum Dis. 2022 Jan;81(1):145-150. doi: 10.1136/annrheumdis-2021-221217.
SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases.
Pmid:
34489305
-
JMIR Med Inform. 2021 Jul 30; 9(7):e26823. doi: 10.2196/26823.
Predicting biologic therapy outcome of patients with Spondyloarthritis: joint models for longitudinal and survival analysis.
Pmid:
34328435
-
Ann Rheum Dis. 2021 Jul; 80(7):930-942. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Pmid:
33504483
-
Acta Reumatol Port. Jan-Mar 2021; 46(1):7-14.
Association of body mass index with Juvenile Idiopathic Arthritis disease activity: a Portuguese and Brazilian collaborative analysis.
Pmid:
33811486
-
Arthritis Care Res (Hoboken). 2022 Jul;74(7):1205-1218. doi: 10.1002/acr.24560.
Real-world six- and twelve-month drug retention, remission, and response rates of secukinumab in 2,017 patients with psoriatic arthritis in thirteen European countries.
Pmid:
33460531
-
Acta Reumatol Port. Oct-Dec 2020; 45(4):245-252.
Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy.
Pmid:
33420771
-
Drugs Aging 2020 Dec; 37(12):899-907. doi: 10.1007/s40266-020-00801-x. Epub 2020 Nov 18.
Safety and effectiveness of biologic disease-modifying antirheumatic drugs in older patients with rheumatoid arthritis: a prospective cohort study.
Pmid:
33205322
-
Acta Reumatol Port. Jul-Sep 2020; 45(3):177-182.
Early retirement attributed to rheumatoid arthritis and its predictors.
Pmid:
33139676
-
Acta Reumatol Port. Jul-Sep 2020; 45(3):170-176.
Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study.
Pmid:
33139681
-
RMD Open. 2020 Sep; 6(3):e001280. doi: 10.1136/rmdopen-2020-001280.
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
Pmid:
32950963
-
Acta Reumatol Port. Oct-Dec 2019; 44(4):281-287.
Loss to follow-up in registries of rheumatic patients treated with biologics: a potential information bias in assessing pharmacovigilance and efficacy outcomes.
Pmid:
32281966
-
BMC Med Inform Decis Mak. 2019 Dec 30; 19(1):289. doi: 10.1186/s12911-019-1013-7.
AliClu - Temporal sequence alignment for clustering longitudinal clinical data.
Pmid:
31888660
-
Acta Reumatol Port. Oct-Dec 2019; 44(4):266-272.
Biologic therapy use and pregnancy outcomes in women with immune-mediated inflammatory rheumatic diseases.
Pmid:
32008032
-
Rheumatology (Oxford). 2020 Jul 1; 59(7):1640-1650. doi: 10.1093/rheumatology/kez427.
Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
Pmid:
31665497
-
Rheumatology (Oxford). 2020 Sep 1; 59(9):2455-2461. doi: 10.1093/rheumatology/kez656.
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.
Pmid:
31960053
-
RMD Open. 2020 Jan; 6(1):e001145. doi: 10.1136/rmdopen-2019-001145.
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI.
Pmid:
32144137
-
Orphanet J Rare Dis. 2020 May 5; 15(1):110. doi: 10.1186/s13023-020-01381-0.
Reuma.pt/vasculitis - the Portuguese vasculitis registry.
Pmid:
32370776
-
Ann Rheum Dis. 2019 Nov;78(11):1536-1544. doi: 10.1136/annrheumdis-2019-215427. Epub 2019 Aug 20.
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
Pmid:
31431486
-
J Rheumatol. 2020 May 1;47(5):690-700. doi: 10.3899/jrheum.181272. Epub 2019 Aug 1.
Real-World Long-Term Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register.
Pmid:
31371659
-
Ann Rheum Dis. 2019 Nov;78(11):1545-1549. doi: 10.1136/annrheumdis-2019-215707. Epub 2019 Jul 30.
Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.
Pmid:
31362994
-
Semin Arthritis Rheum. 2020 Feb;50(1):17-24. doi: 10.1016/j.semarthrit.2019.06.020. Epub 2019 Jun 28.
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
Pmid:
31280937
-
Rheumatology (Oxford). 2019 Dec 1;58(12):2221-2229. doi: 10.1093/rheumatology/kez221.
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.
Pmid:
31209481
-
Acta Reumatol Port. 2019 Apr-Jun;44(2):103-113.
Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Pmid:
31243259
-
Acta Reumatol Port. 2019 Jan-Mar;44(1):57-64.
Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt.
Pmid:
31249276
-
RMD Open. 2018 Nov 5;4(2):e000809. doi: 10.1136/rmdopen-2018-000809.
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries.
Pmid:
30488002
-
Ann Rheum Dis. 2018 Sep;77(9):1276-1282. doi: 10.1136/annrheumdis-2017-212845. Epub 2018 May 5.
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Pmid:
29730637
-
Front Med (Lausanne). 2018 Mar 8;5:40. doi: 10.3389/fmed.2018.00040.
Common evaluations of disease activity in rheumatoid arthritis reach discordant classifications across different populations.
Pmid:
29662880
-
Acta Reumatol Port. 2018 Jan-Mar;43(1):8-9.
Reuma.pt - structure and innovation.
Pmid:
29602162
-
Acta Reumatol Port. 2018 Jan-Mar;43(1):6-7.
Reuma.pt - the start and the purpose.
Pmid:
29602161
-
Ann Rheum Dis. 2017 Dec;76(12):2025-2030. doi: 10.1136/annrheumdis-2017-211623. Epub 2017 Aug 19.
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.
Pmid:
28822981
-
Acta Reumatol Port. 2017 Oct-Dec;42(4):287-299.
Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt - EARLY PsA.
Pmid:
29342473
-
Acta Reumatol Port. 2017 Jul-Sep;42(3):232-239.
Reuma.pt contribution to the knowledge of immune-mediated systemic rheumatic diseases.
Pmid:
28917219
-
Acta Reumatol Port. 2017 Jun;42(Apr-Jun):141-149.
Real-life effectiveness of Golimumab in biologic-naïve patients with rheumatoid arthritis - data from the Rheumatic Diseases Portuguese Register (Reuma.pt).
Pmid:
28371797
-
Clin Rheumatol. 2017 Apr;36(4):773-779.
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).
Pmid:
27966068
-
Pediatr Rheumatol Online J. 2017 Apr 19;15(1):31. doi: 10.1186/s12969-017-0161-5.
A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities.
Pmid:
28424093
-
Front Med (Lausanne). 2017 Mar 1;4:12. doi: 10.3389/fmed.2017.00012. eCollection 2017.149.
Genetic Screening of Mutations Associated with Fabry Disease in a Nationwide Cohort of Juvenile Idiopathic Arthritis Patients.
Pmid:
28299312
-
Ann Rheum Dis. 2017 Feb;76(2):386-391. doi: 10.1136/annrheumdis-2016-209285. Epub 2016 Jun 15.
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
Pmid:
27307502
-
J Rheumatol. 2017 Feb;44(2):162-169.
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.
Pmid:
28089978
-
Acta Reumatol Port. 2017 Jan-Mar;42(1):55-65.
Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis.
Pmid:
27750274
-
RMD Open. 2016 Sep 22;2(2):e000304. eCollection 2016.
Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage.
Pmid:
27752356
-
EBioMedicine. 2016 Sep;11:302-306. doi: 10.1016/j.ebiom.2016.08.024. Epub 2016 Aug 18.
Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.
Pmid:
27558858
-
Ann Rheum Dis. 2016 Jul;75(7):1336-42. doi: 10.1136/annrheumdis-2015-207760. Epub 2015 Sep 15.
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.
Pmid:
26374404
-
Ann Rheum Dis. 2016 Jun 15. pii: annrheumdis-2016-209285. doi: 10.1136/annrheumdis-2016-209285.
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
Pmid:
27307502
-
Arthritis Rheumatol. 2016 Jun 6. doi: 10.1002/art.39772.
Effect of comedication with conventional synthetic DMARDs on TNF inhibitors-retention in patients with spondyloarthritis: A prospective cohort.
Pmid:
27273894
-
Arthritis Rheumatol. 2016 Jun;68(6):1346-52. doi: 10.1002/art.39595.
Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
Pmid:
26815727
-
Rheumatol Int. 2016 Jul;36(7):955-60. doi: 10.1007/s00296-016-3450-2. Epub 2016 Mar 15.
Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register.
Pmid:
26979603
-
Acta Med Port. 2016 Feb;29(2):83-4. doi: 10.20344/amp.7243. Epub 2016 Feb 29.
Reuma.pt - case study.
Pmid:
27234945
-
Arthritis Res Ther. 2016 Feb 16;18:50. doi: 10.1186/s13075-016-0951-z.
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.
Pmid:
26883119
-
Rheumatology (Oxford). 2016 Feb;55(2):230-6. doi: 10.1093/rheumatology/kev297. Epub 2015 Aug 27.
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Pmid:
26316581
-
Joint Bone Spine. 2015 Oct;82(5):378-80. doi: 10.1016/j.jbspin.2015.01.004. Epub 2015 Apr 23.
The weaker sex: Characterization of gender disparities in a nationwide lupus register (Reuma.pt/SLE).
Pmid:
25921914
-
J Immunol Res. 2015;2015:706515. doi: 10.1155/2015/706515. Epub 2015 Oct 4.
Genetic Predictors of Poor Prognosis in Portuguese Patients with Juvenile Idiopathic Arthritis: Data from Reuma.pt.
Pmid:
26504858
-
Arthritis Care Res (Hoboken). 2015 Aug;67(8):1180-5. doi: 10.1002/acr.22539.
Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort.
Pmid:
25581417
-
Rheumatology (Oxford). 2015 Jun;54(6):1074-9. doi: 10.1093/rheumatology/keu446. Epub 2014 Nov 27.
The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.
Pmid:
25433042
-
RMD Open. 2015 Apr 30;1(1):e000040. doi: 10.1136/rmdopen-2014-000040. eCollection 2015.
The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries.
Pmid:
26509062
-
Biomed Res Int. 2015;2015:279890. Epub 2015 Apr 27.
Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt.
Pmid:
26000286
-
Biomed Res Int. 2015;2015:490295. Epub 2015 Mar 5.
TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy.
Pmid:
25834819
-
Lupus. 2015 Mar;24(3):256-62. doi: 10.1177/0961203314555172.Epub 2014 Oct 15.
Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry.
Pmid:
25318970
-
Rheumatology (Oxford). 2015 Feb;54(2):286-91. doi: 10.1093/rheumatology/keu313. Epub 2014 Aug 29.
DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt.
Pmid:
25173347
-
Arthritis Care Res (Hoboken). 2014 Apr;66(4):585-591. doi: 10.1002/acr.22215.
Using the Juvenile Arthritis Disease Activity Score Based on Erythrocyte Sedimentation Rate or C-Reactive Protein Level: Results From the Portuguese Register
Pmid:
25354266
-
PLoS Genet. 2013 Mar;9(3):e1003394. doi: 10.1371/journal.pgen.1003394. Epub 2013 Mar 28.
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis
Pmid:
23555300
-
Rheumatology (Oxford). 2012 Nov;51(11):2020-6. doi: 10.1093/rheumatology/kes184. Epub 2012 Jul 28.
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis.
Pmid:
22843791
-
Acta Reumatol Port. 2011 Jul;36(3):234-242.
Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive?
Pmid:
22116079
-
Acta Reumatol Port. 2011 Jan-Mar;36(1):45-56.
Reuma.pt - the rheumatic diseases portuguese register.
Pmid:
21483280
-
Acta Reumatol Port. 2010 Oct-Dec;35(5):456-62.
Velocidade de sedimentação ou proteína C reactiva, que variáveis utilizar na avaliação clínica dos doentes com artrite reumatóide?
Pmid:
21245814
-
Acta Reumatol Port. 2010 Apr-Jun;35(2):176-83.
BioRePortAP, an electronic clinical record coupled with a database: an example of its use in a single centre.
Pmid:
20734541